22342346|t|T-817MA, a novel neurotrophic agent, ameliorates loss of GABAergic parvalbumin-positive neurons and sensorimotor gating deficits in rats transiently exposed to MK-801 in the neonatal period.
22342346|a|T-817MA [1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}azetidin-3-ol maleate] is a newly synthesized neuroprotective agent for the treatment of psychiatric disorders characterized by cognitive disturbances, such as Alzheimer's disease. Cognitive impairment has also been suggested to be a cardinal feature of schizophrenia. We sought to determine whether T-817MA would ameliorate sensorimotor gating deficits and loss of parvalbumin (PV)-positive gamma-aminobutyric acid (GABA) neurons in the brain of rats transiently exposed to MK-801, an N-methyl-d-aspartate receptor blocker, in the neonatal stage, as an animal model of schizophrenia. Prepulse inhibition (PPI) was examined in rats treated neonatally with MK-801 (postnatal day; PD 7-10, 0.2 mg/kg/day, s.c.) or vehicle at PD 35 and PD 63. The number of PV-positive GABAergic neurons in the medial prefrontal cortex (mPFC) and the hippocampus was measured after the behavioral assessments. T-817MA (10 or 20 mg/kg) or vehicle was administered for 14 days (on PD 49-62). Administration of T-817MA at 20 mg/kg, but not 10 mg/kg, ameliorated PPI deficits and completely reversed the decrease in the number of PV-positive GABAergic neurons in rats given MK-801. These results indicate that T-817MA may provide a novel therapeutic approach for the treatment of cognitive deficits of schizophrenia.
22342346	0	7	T-817MA	Chemical	MESH:C503102
22342346	67	78	parvalbumin	Gene	25269
22342346	113	128	gating deficits	Disease	MESH:D009461
22342346	132	136	rats	Species	10116
22342346	160	166	MK-801	Chemical	MESH:D016291
22342346	191	198	T-817MA	Chemical	MESH:C503102
22342346	200	265	1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}azetidin-3-ol maleate	Chemical	-
22342346	333	354	psychiatric disorders	Disease	MESH:D001523
22342346	372	394	cognitive disturbances	Disease	MESH:D003072
22342346	404	423	Alzheimer's disease	Disease	MESH:D000544
22342346	425	445	Cognitive impairment	Disease	MESH:D003072
22342346	498	511	schizophrenia	Disease	MESH:D012559
22342346	544	551	T-817MA	Chemical	MESH:C503102
22342346	582	597	gating deficits	Disease	MESH:D009461
22342346	610	621	parvalbumin	Gene	25269
22342346	623	625	PV	Gene	25269
22342346	636	659	gamma-aminobutyric acid	Chemical	MESH:D005680
22342346	661	665	GABA	Chemical	MESH:D005680
22342346	691	695	rats	Species	10116
22342346	719	725	MK-801	Chemical	MESH:D016291
22342346	814	827	schizophrenia	Disease	MESH:D012559
22342346	871	875	rats	Species	10116
22342346	900	906	MK-801	Chemical	MESH:D016291
22342346	923	930	PD 7-10	Chemical	-
22342346	998	1000	PV	Gene	25269
22342346	1134	1141	T-817MA	Chemical	MESH:C503102
22342346	1232	1239	T-817MA	Chemical	MESH:C503102
22342346	1350	1352	PV	Gene	25269
22342346	1383	1387	rats	Species	10116
22342346	1394	1400	MK-801	Chemical	MESH:D016291
22342346	1430	1437	T-817MA	Chemical	MESH:C503102
22342346	1500	1518	cognitive deficits	Disease	MESH:D003072
22342346	1522	1535	schizophrenia	Disease	MESH:D012559
22342346	Positive_Correlation	MESH:D016291	MESH:D009461
22342346	Negative_Correlation	MESH:C503102	MESH:D001523
22342346	Negative_Correlation	MESH:C503102	MESH:D009461
22342346	Negative_Correlation	MESH:C503102	MESH:D000544
22342346	Association	MESH:D005680	25269
22342346	Negative_Correlation	MESH:C503102	MESH:D003072
22342346	Negative_Correlation	MESH:C503102	25269
22342346	Negative_Correlation	MESH:C503102	MESH:D012559

